Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) have received an average rating of "Buy" from the eight brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have given a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $10.90.
Several analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of TriSalus Life Sciences from a "hold" rating to a "sell" rating in a research note on Sunday, September 28th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of TriSalus Life Sciences in a research note on Wednesday, October 8th.
Check Out Our Latest Analysis on TriSalus Life Sciences
TriSalus Life Sciences Stock Performance
TriSalus Life Sciences stock opened at $4.68 on Wednesday. The company has a 50 day moving average price of $4.68 and a 200-day moving average price of $5.02. TriSalus Life Sciences has a fifty-two week low of $3.42 and a fifty-two week high of $5.88. The company has a market capitalization of $233.38 million, a PE ratio of -3.97 and a beta of 0.47.
TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05). The firm had revenue of $11.21 million for the quarter, compared to analysts' expectations of $10.69 million. TriSalus Life Sciences has set its FY 2025 guidance at EPS. On average, analysts forecast that TriSalus Life Sciences will post -1.55 earnings per share for the current year.
Hedge Funds Weigh In On TriSalus Life Sciences
A number of large investors have recently bought and sold shares of TLSI. Police & Firemen s Retirement System of New Jersey bought a new position in TriSalus Life Sciences in the second quarter worth approximately $29,000. JPMorgan Chase & Co. raised its stake in TriSalus Life Sciences by 35,804.8% in the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company's stock worth $41,000 after buying an additional 7,519 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in TriSalus Life Sciences in the second quarter worth approximately $47,000. Charles Schwab Investment Management Inc. bought a new position in TriSalus Life Sciences in the first quarter worth approximately $55,000. Finally, New York State Common Retirement Fund acquired a new position in shares of TriSalus Life Sciences during the second quarter worth $108,000. Institutional investors own 2.58% of the company's stock.
TriSalus Life Sciences Company Profile
(
Get Free Report)
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TriSalus Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriSalus Life Sciences wasn't on the list.
While TriSalus Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
